Skyrizi (risankizumab) is the first IL-23-selective drug to be cleared for the inflammatory bowel disease – ahead of rivals like Johnson & Johnson's Tremfya (guselkumab), and Sun Pharma's Ilumya ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

In terms of competition, there are currently only two other IL-23 inhibitors approved in the US besides Tremfya – Eli Lilly’s Omvoh (mirikizumab) and AbbVie’s Skyrizi (risankizumab).

Spherix compared the level of activity favorably to other launches, noting that awareness levels were higher for Bimzelx than for Rinvoq and Skyrizi and Johnson & Johnson’s Tremfya at the same ...

Some analysts meanwhile have suggested Tremfya’s biggest challenge will be to stay ahead of Skyrizi, which has been proposed as a ‘best-in-class’ drug with efficacy that is at least as good ...